Geron Corporation (GERN)

Market Cap	802.52M
Revenue (ttm)	116.29M
Net Income (ttm)	-139.02M
Shares Out	636.92M
EPS (ttm)	-0.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,645,744
Open	1.295
Previous Close	1.310
Day's Range	1.250 - 1.315
52-Week Range	1.170 - 5.340
Beta	0.76
Analysts	Buy
Price Target	5.13 (+307.14%)
Earnings Date	May 7, 2025

About GERN

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 30, 1996
• Employees: 229
• Stock Exchange: NASDAQ
• Ticker Symbol: GERN
• Website: https://www.geron.com

Financial Performance

In 2024, Geron's revenue was $76.99 million, an increase of 32386.92% compared to the previous year's $237,000. Losses were -$174.57 million, -5.19% less than in 2023.

Analyst Forecast

According to 9 analysts, the average rating for GERN stock is "Buy." The 12-month stock price forecast is $5.13, which is an increase of 307.14% from the latest price.

Price Target

$5.13

(307.14% upside)

Analyst Consensus: Buy